Posted by Michael Wonder on 13 Jan 2021
Innovent announces NMPA acceptance of a supplemental new drug application for Tyvyt (sintilimab injection) in combination with Byvasda (bevacizumab injection) as first-line therapy in hepatocellular carcinoma
12 January 2021 - Innovent Biologics today announced that the National Medical Products Administration of China has accepted the supplemental new drug application for Tyvyt (sintilimab injection) in combination with Bvvasda (bevacizumab injection) as first-line therapy for patients with hepatocellular carcinoma.
This is the fifth new drug application of Tyvyt that has been accepted for review by NMPA. Meanwhile, this application also seeks the fourth indication for Byvasda.
